Physician profile
Chikoti Wheat
NPI 1619210598
$152,260.35
in general payments reported to CMS, 2019-2025
48 companies · $93K in 2025
The $93K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,637 · 2020: $895 · 2021: $1,354 · 2022: $3,457 · 2023: $17K · 2024: $34K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $47K · Food and Beverage: $27K · Travel and Lodging: $7,673 · Honoraria: $2,750 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,851.84 |
| Consulting Fee | $47,108.28 |
| Food and Beverage | $27,051.02 |
| Travel and Lodging | $7,672.52 |
| Honoraria | $2,750.00 |
| Education | $483.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $66,973.43 | 2019-2025 | |
| Leo Pharma INC. | $20,017.63 | 2019-2025 | Anzupgo, Adbry, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $16,929.90 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $12,717.34 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $4,978.16 | 2019-2025 | |
| Abbvie INC. | $4,051.86 | 2019-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $3,994.25 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $3,311.71 | 2019-2025 | Dupixent, Libtayo |
| Lnhc, INC | $2,904.02 | 2025 | Zelsuvmi |
| Janssen Biotech, INC. | $2,854.35 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $2,682.92 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,823.82 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $1,355.54 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $1,346.38 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $1,264.06 | 2022-2025 | Opzelura, Opzelura |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chikoti Wheat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.